Anavex Life Sciences Corp. (0HFR.L)
0HFR.L Stock Price Chart
Explore Anavex Life Sciences Corp. interactive price chart. Choose custom timeframes to analyze 0HFR.L price movements and trends.
0HFR.L Company Profile
Discover essential business fundamentals and corporate details for Anavex Life Sciences Corp. (0HFR.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
42.00
Website
https://www.anavex.comCEO
Christopher U. Missling
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
0HFR.L Financial Timeline
Browse a chronological timeline of Anavex Life Sciences Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 22 Dec 2025
Upcoming earnings on 4 Aug 2025
Earnings released on 13 May 2025
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%.
Earnings released on 12 Feb 2025
EPS came in at -$0.14 surpassing the estimated -$0.17 by +15.99%.
Earnings released on 23 Dec 2024
EPS came in at -$0.14 surpassing the estimated -$0.16 by +14.28%.
Earnings released on 6 Aug 2024
EPS came in at -$0.14 surpassing the estimated -$0.16 by +9.70%.
Earnings released on 9 May 2024
EPS came in at -$0.13 falling short of the estimated -$0.11 by -16.26%.
Earnings released on 4 Mar 2024
EPS came in at -$0.11 surpassing the estimated -$0.15 by +27.55%.
Earnings released on 27 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.15 by +15.61%.
Earnings released on 8 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.17 by +16.32%.
Earnings released on 9 May 2023
EPS came in at -$0.17 surpassing the estimated -$0.19 by +11.09%.
Earnings released on 7 Feb 2023
EPS came in at -$0.17 surpassing the estimated -$0.19 by +11.28%.
Earnings released on 28 Nov 2022
EPS came in at -$0.18 falling short of the estimated -$0.17 by -11.84%.
Earnings released on 30 Jun 2022
EPS came in at -$0.16 falling short of the estimated -$0.15 by -3.82%.
Earnings released on 31 Mar 2022
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.89%.
Earnings released on 31 Dec 2021
EPS came in at -$0.14.
Earnings released on 30 Sept 2021
EPS came in at -$0.15 surpassing the estimated -$0.16 by +0.42%.
Earnings released on 30 Jun 2021
EPS came in at -$0.14.
Earnings released on 31 Mar 2021
EPS came in at -$0.12.
Earnings released on 31 Dec 2020
EPS came in at -$0.12.
Earnings released on 30 Sept 2020
EPS came in at -$0.10.
0HFR.L Stock Performance
Access detailed 0HFR.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.